Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance.

Transl Lung Cancer Res · 2023 · PMC10183387 · PMID 37197627

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendP=0.08so close (0.05 < p ≤ 0.1)

Patients who received prior afatinib showed a trend towards a lower ORR of 32% with osimertinib use vs. 46.5% in patients who received prior 1G EGFR TKI (P=0.08) despite a similar rate of T790M positivity (79.9% with 1G-TKI and 72.3% with afatinib use).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.